AGIOS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 251.57 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-02-12
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 251.57K shares, a 341.98% increase from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 56.92K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|
| 2025-12-31 | 251.57K shares 10-K · filed 2026-02-12 |
| 2024-12-31 | 56.92K shares 10-K · filed 2025-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |